Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
<strong>Background<br></strong> Aspirin is widely used for cardioprotection with its antiplatelet effects due to the blocking of thromboxane A2 production. However, it has been suggested that platelet abnormalities in those with diabetes prevent adequate suppression with once daily...
Main Authors: | Parish, S, Buck, G, Aung, T, Mafham, M, Clark, S, Hill, M, Collins, R, Bowman, L, Armitage, J |
---|---|
Other Authors: | ASCEND Study Collaborative Group |
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2023
|
Similar Items
-
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
by: Sarah Parish, et al.
Published: (2023-03-01) -
Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
by: Aung, T, et al.
Published: (2017) -
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
by: Petrucci, G, et al.
Published: (2024) -
Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2
by: Angela van der Plas, et al.
Published: (2018-01-01) -
Urinary leukotriene E4 and 11-dehydro-thromboxane B2 excretion in children with bronchial asthma
by: Kaori Yoshikawa, et al.
Published: (2004-01-01)